Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of olaparib plus bevacizumab with HRD assessment in advanced ovarian, fallopian tube, or primary peritoneal cancer
2021-004455-17Phase 2Active
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Percentage of HR status agreement between VHIO 300 test and SOPHiA DDM HRD Solution. Started Oct 2022; status: active.
02
Drugs
olaparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2021-004455-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004455-17.